Meredith Adler Barclays Capital
The buy side says: “She stands head and shoulders above her peers.”
It’s nine straight years at No. 1 for Meredith Adler, who “draws on lengthy experience to make quick reads on situations and evolving trends and their impact on companies and the industry as a whole,” extols one satisfied client. Case in point: The Barclays Capital analyst urged investors to buy NBTY, a Ronkonkoma, New York-based nutritional-supplements manufacturer that markets its products via its web site, as well as through drug and general merchandise stores. Adler, 56, recommended the stock in late April, at $39.04, on the belief that the company stood to gain from the medical community’s growing support of nutrient supplements. By mid-July, when Adler suspended coverage owing to BarCap’s involvement in the Carlyle Group’s $3.8 billion buyout of NBTY, the stock had advanced a very healthy 37.7 percent, to $53.74. During the same period the sector slid 9.5 percent.
